These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition. Sun S; Pithavala YK; Martini JF; Chen J J Clin Pharmacol; 2022 Sep; 62(9):1170-1176. PubMed ID: 35373356 [TBL] [Abstract][Full Text] [Related]
6. Lorlatinib as a treatment for ALK-positive lung cancer. Baba K; Goto Y Future Oncol; 2022 Aug; 18(24):2745-2766. PubMed ID: 35787143 [TBL] [Abstract][Full Text] [Related]
7. Pan-HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK-rearranged lung cancer. Taniguchi H; Akagi K; Dotsu Y; Yamada T; Ono S; Imamura E; Gyotoku H; Takemoto S; Yamaguchi H; Sen T; Yano S; Mukae H Cancer Sci; 2023 Jan; 114(1):164-173. PubMed ID: 36086904 [TBL] [Abstract][Full Text] [Related]
8. Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis. Zhang X; Tong J; Wang T; Wang T; Xu L; Wang Z; Hou T; Pan P Comput Biol Med; 2024 Feb; 169():107815. PubMed ID: 38128254 [TBL] [Abstract][Full Text] [Related]
9. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378 [TBL] [Abstract][Full Text] [Related]
10. A pragmatic guide for management of adverse events associated with lorlatinib. Liu G; Mazieres J; Stratmann J; Ou SI; Mok T; Grizzard M; Goto Y; Felip E; Solomon BJ; Bauer TM Lung Cancer; 2024 May; 191():107535. PubMed ID: 38554546 [TBL] [Abstract][Full Text] [Related]
11. An update on lorlatinib: a novel first line treatment for Riudavets M; Planchard D Expert Opin Pharmacother; 2023 Feb; 24(3):291-299. PubMed ID: 36542835 [TBL] [Abstract][Full Text] [Related]
12. Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse. Dagogo-Jack I; Oxnard GR; Evangelist M; Digumarthy SR; Lin JJ; Gainor JF; Murphy JF; Rabin MS; Heist RS; Muzikansky A; Shaw AT JCO Precis Oncol; 2022 May; 6():e2100522. PubMed ID: 35584349 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological and clinical properties of lorlatinib in the treatment of El Darsa H; Abdel-Rahman O; Sangha R Expert Opin Pharmacother; 2020 Sep; 21(13):1547-1554. PubMed ID: 32511029 [TBL] [Abstract][Full Text] [Related]
14. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Shiba-Ishii A; Johnson TW; Dagogo-Jack I; Mino-Kenudson M; Johnson TR; Wei P; Weinrich SL; McTigue MA; Walcott MA; Nguyen-Phuong L; Dionne K; Acker A; Kiedrowski LA; Do A; Peterson JL; Barth JL; Yeap BY; Gainor JF; Lin JJ; Yoda S; Hata AN Nat Cancer; 2022 Jun; 3(6):710-722. PubMed ID: 35726063 [TBL] [Abstract][Full Text] [Related]
15. Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase (ALK)-positive lung cancer and multiple brain metastases. Murakami Y; Kawashima Y; Chiba S; Hara S; Yamazaki Y; Doman T; Saito S; Odaka T; Ogasawara T; Shimizu H; Sugisaka J; Aiba T; Toi Y; Yamanda S; Kimura Y; Sugawara S Cancer Rep (Hoboken); 2024 Feb; 7(2):e1981. PubMed ID: 38212894 [TBL] [Abstract][Full Text] [Related]
16. Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib: A case report. Nakashima K; Demura Y; Kurokawa K; Takeda T; Jikuya N; Oi M; Tada T; Akai M; Ishizuka T Medicine (Baltimore); 2021 Oct; 100(39):e27385. PubMed ID: 34596160 [TBL] [Abstract][Full Text] [Related]
17. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy. Jóri B; Falk M; Hövel I; Weist P; Tiemann M; Heukamp LC; Griesinger F Curr Oncol; 2022 Sep; 29(9):6628-6634. PubMed ID: 36135089 [TBL] [Abstract][Full Text] [Related]
18. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study. Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682 [TBL] [Abstract][Full Text] [Related]
19. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186 [TBL] [Abstract][Full Text] [Related]
20. Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients. Lee PH; Chen KC; Hsu KH; Huang YH; Tseng JS; Yang TY; Chang GC Anticancer Drugs; 2021 Nov; 32(10):1099-1104. PubMed ID: 34232936 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]